181 related articles for article (PubMed ID: 8092829)
1. Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma.
Berenguer J; Ali NM; Allende MC; Lee J; Garrett K; Battaglia S; Piscitelli SC; Rinaldi MG; Pizzo PA; Walsh TJ
Antimicrob Agents Chemother; 1994 Jun; 38(6):1303-8. PubMed ID: 8092829
[TBL] [Abstract][Full Text] [Related]
2. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372
[TBL] [Abstract][Full Text] [Related]
3. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Prince RA; Chi J; Kontoyiannis DP
Antimicrob Agents Chemother; 2002 Oct; 46(10):3208-14. PubMed ID: 12234846
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis.
Patterson TF; Fothergill AW; Rinaldi MG
Antimicrob Agents Chemother; 1993 Nov; 37(11):2307-10. PubMed ID: 8285610
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis.
Denning DW; Hall L; Jackson M; Hollis S
Antimicrob Agents Chemother; 1995 Aug; 39(8):1809-14. PubMed ID: 7486923
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis.
Allende MC; Lee JW; Francis P; Garrett K; Dollenberg H; Berenguer J; Lyman CA; Pizzo PA; Walsh TJ
Antimicrob Agents Chemother; 1994 Mar; 38(3):518-22. PubMed ID: 8203848
[TBL] [Abstract][Full Text] [Related]
7. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.
Patterson TF; Kirkpatrick WR; White M; Hiemenz JW; Wingard JR; Dupont B; Rinaldi MG; Stevens DA; Graybill JR
Medicine (Baltimore); 2000 Jul; 79(4):250-60. PubMed ID: 10941354
[TBL] [Abstract][Full Text] [Related]
8. Itraconazole for the treatment of pulmonary aspergillosis in heart transplant recipients.
Nanas JN; Saroglou G; Anastasiou-Nana MI; Kostis EB; Petrochilou-Paschou VP; Kontoyannis DA; Stamatelopoulos SF; Moulopoulos SD
Clin Transplant; 1998 Feb; 12(1):30-4. PubMed ID: 9541420
[TBL] [Abstract][Full Text] [Related]
9. Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis.
Petraitis V; Petraitiene R; Solomon J; Kelaher AM; Murray HA; Mya-San C; Bhandary AK; Sein T; Avila NA; Basevicius A; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2006 Apr; 50(4):1510-7. PubMed ID: 16569871
[TBL] [Abstract][Full Text] [Related]
10. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Bell A; Callender DP; Sein T; Schaufele RL; McMillian CL; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 1998 Nov; 42(11):2898-905. PubMed ID: 9797223
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis.
Allendoerfer R; Loebenberg D; Rinaldi MG; Graybill JR
Antimicrob Agents Chemother; 1995 Jun; 39(6):1345-8. PubMed ID: 7574528
[TBL] [Abstract][Full Text] [Related]
12. [Curative treatment of invasive aspergillosis].
Dupont B
Pathol Biol (Paris); 1994 Sep; 42(7):688-93. PubMed ID: 7877863
[TBL] [Abstract][Full Text] [Related]
13. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis.
Dannaoui E; Borel E; Persat F; Piens MA; Picot S
J Med Microbiol; 2000 Jul; 49(7):601-606. PubMed ID: 10882084
[TBL] [Abstract][Full Text] [Related]
14. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis.
Caillot D
Acta Haematol; 2003; 109(3):111-8. PubMed ID: 12714819
[TBL] [Abstract][Full Text] [Related]
15. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism.
Schaffner A; Böhler A
Mycoses; 1993; 36(11-12):421-4. PubMed ID: 7935575
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304.
Defaveri J; Salazar MH; Rinaldi MG; Graybill JR
Am Rev Respir Dis; 1990 Sep; 142(3):512-5. PubMed ID: 2202244
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of intravenous itraconazole against invasive pulmonary aspergillosis in neutropenic mice.
Tansho S; Abe S; Ishibashi H; Torii S; Otani H; Ono Y; Yamaguchi H
J Infect Chemother; 2006 Dec; 12(6):355-62. PubMed ID: 17235640
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.
Wiederhold NP; Tam VH; Chi J; Prince RA; Kontoyiannis DP; Lewis RE
Antimicrob Agents Chemother; 2006 Feb; 50(2):469-73. PubMed ID: 16436698
[TBL] [Abstract][Full Text] [Related]
19. Itraconazole--perspectives for the management of invasive aspergillosis.
Groll AH
Mycoses; 2002; 45 Suppl 3():48-55. PubMed ID: 12690972
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients.
Dannaoui E; Meletiadis J; Tortorano AM; Symoens F; Nolard N; Viviani MA; Piens MA; Lebeau B; Verweij PE; Grillot R; And The Ebga Network
J Med Microbiol; 2004 Feb; 53(Pt 2):129-134. PubMed ID: 14729934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
